Clinical trials: Solid Malignancy
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 42 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Solid Tumor, HER2 Gene Mutation
The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor
This is an open-label, Phase 2 study exploring the efficacy and safety of 马来酸Pyrotinib Maleate Tablets in patients with solid tumors with activating（harmful） HER2 mutations or with HER2 gene amplification or immunohistochemical…
- Conditions
- Solid Tumor, HER2 Gene Mutation, HER-2 Gene Amplification, HER-2 Protein Overexpression
- Trial name
- NCT04179656
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tianjin Medical University Second Hospital
Ovarian Cancer, Colorectal Cancer
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian, prostate, colorectal or non-small…
- Conditions
- Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
- Trial name
- NCT00132522
- Testing
- EMD 273066
- Where
- 5 sites in United States, Switzerland
- Volunteers
- 45 people
- Sponsor
- EMD Serono
Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
This phase I trial is studying the side effects and best dose of giving tanespimycin together with bortezomib in treating patients with advanced solid tumors or lymphomas.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00096005
- Testing
- tanespimycin, bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
- Conditions
- Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT07021066
- Testing
- BL-M05D1
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- SystImmune Inc.
Non-Hodgkin Lymphoma, Neoplasms
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
The primary purpose of this open-label study is to investigate the interaction of ketoconazole, a liver enzyme inhibitor, on oral LBH589 in adult patients with advanced solid tumors.
- Trial name
- NCT00503451
- Testing
- LBH589
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
RP2-001-18 is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP2 in adult subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended…
- Trial name
- NCT04336241
- Testing
- RP2, nivolumab
- Where
- 6 sites in Spain, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Replimune, Inc.
Solid Tumor, Adult
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in…
- Trial name
- NCT06026254
- Testing
- IMSA101, Immune Checkpoint Inhibitor
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- ImmuneSensor Therapeutics Inc.
Cancer
Risk Factors for Thromboembolic and Infectious Complications Related to Percutaneous Central Venous Catheters in Cancer - Prospective Multicenter Study
The purpose of this study is to identify risk factors for thromboembolic and /or infectious complications in 3,000 patients with solid tumor and receiving a Percutaneous Central Venous Catheter (PCVC).
- Trial name
- ONCOCIP (NCT02025894)
- Where
- 27 sites in France
- Volunteers
- 3,032 people
- Sponsor
- Institut de Cancérologie de la Loire
Neuroblastoma, Sarcoma
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Background: Pediatric solid tumors (Ewing's sarcoma, rhabdomyosarcoma, and neuroblastoma) are often difficult to cure with standard treatment.
- Conditions
- Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar
- Trial name
- NCT00923351
- Testing
- Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Abdominal Neoplasms
22 Gauge Needle for EUS Guided Tissue Acquisition of Samples for Histologic Examination
To determine the yield of tissue biopsy specimen and the diagnostic accuracy of tissue acquisition using a newly developed 22 gauge needle in patients with solid lesions throughout the GI tract.
- Trial name
- EUSFNTA (NCT04032951)
- Testing
- Fine Needle Tissue Acquisition
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Catholic University of the Sacred Heart
Advanced Refractory Solid Tumors
Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
T-1101 (Tosylate) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by Taivex Therapeutics Corp. T-1101 (Tosylate) is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT04685473
- Testing
- T-1101 (Tosylate)
- Where
- 2 sites in Taiwan
- Volunteers
- 24 people
- Sponsor
- Taivex Therapeutics Corporation
Advanced Ovarian Cancer, Primary Peritoneal Cancer
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Background: The poly (ADP-ribose) polymerase (PARP) family of enzymes is critical for maintaining genomic stability by regulating a variety of deoxyribonucleic acid (DNA) damage repair mechanisms.
- Conditions
- Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors
- Trial name
- NCT01989546
- Testing
- BMN 673
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
This study is a single-center exploratory clinical trial. It is estimated that 9-24 subjects will be enrolled. The "3+3" dose escalation design is adopted.
- Trial name
- NCT05166070
- Testing
- RD133
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Expressive Writing for the Management of Stress in Cancer Survivors
This clinical trial evaluates the effect of expressive writing for the management of stress in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in cancer survivors related to concerns about…
- Trial name
- NCT04776941
- Testing
- Behavioral Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 414 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
INVAC-1 Anti-Cancer hTERT DNA Immunotherapy
INVAC-1 is intended to be used for the treatment of adult patients with advanced solid tumors unresponsive to currently available therapies, or for whom no standard therapy is available.
- Trial name
- NCT02301754
- Testing
- INVAC-1
- Where
- 2 sites in France
- Volunteers
- 26 people
- Sponsor
- Invectys
Advanced Malignant Solid Tumors
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-295S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor.
- Trial name
- NCT04908046
- Testing
- HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Hutchmed
Advanced Relapsed Tumors, Refractory Solid Tumors
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
This is an open-label Phase 1a/b dose-escalation study to assess the safety, tolerability, and PK of OMP-131R10 as a single agent for advanced solid tumors and in subjects with metastatic colorectal cancer.
- Trial name
- NCT02482441
- Testing
- OMP-131R10, FOLFIRI
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Pediatric Solid Tumors
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
The purpose of this study is to test the safety and effectiveness of 2 drugs, perifosine in combination with temsirolimus in children with solid tumors.
- Trial name
- NCT01049841
- Testing
- perifosine + temsirolimus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center